New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 28, 2013
09:26 EDTBBRY, AFAM, GTIV, AMED, PFE, ABFS, SNY, BIIB, ACI, MCP, DNDN, ACN, LHCGOn The Fly: Pre-market Movers
HIGHER: Dendreon (DNDN), up 9.8% after getting positive EU opinion for Provenge drug... Arkansas Best (ABFS), up 10% after ABF Freight System employees represented by Teamsters ratify five-year national labor agreement... Molycorp (MCP), up 7.8% after SEC completes investigation with no enforcement action recommended... Arch Coal (ACI), up 8.9% after announcing will sell non-core Utah operations to Bowie Resources for $435M... Biogen (BIIB), up 5.8% after the European Medicines Agency granted Sanofi's multiple sclerosis drug Aubagio "new active substance" status. Sanofi, which also received a positive CHMP opinion for Lemtrada, up 1.5%... Pfizer (PFE), up 1% after boosting share buyback program by $10B. DOWN AFTER EARNINGS: BlackBerry (BBRY), down 23%... Accenture (ACN), down 9%... Nike (NKE), down 0.8%. ALSO LOWER: Home health agencies, including Amedisys (AMED), down 21%, Gentiva Health (GTIV), down 16%, Almost Family (AFAM), down 13%, and LHC Group (LHCG), down 12%, after the Centers for Medicare & Medicaid Services proposed 2014 reimbursement cuts.
News For BBRY;ACN;DNDN;MCP;ACI;BIIB;SNY;ABFS;PFE;AMED;GTIV;AFAM;LHCG From The Last 14 Days
Check below for free stories on BBRY;ACN;DNDN;MCP;ACI;BIIB;SNY;ABFS;PFE;AMED;GTIV;AFAM;LHCG the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
September 15, 2014
07:27 EDTPFEPfizer acquisition could drive shares higher, says JPMorgan
Subscribe for More Information
September 14, 2014
13:32 EDTPFEPfizer shares look cheap, Barron's says
Subscribe for More Information
September 12, 2014
10:32 EDTPFEPfizer CEO says company still open to inversion deal, FT says
Pfizer (PFE) CEO Ian Read said U.S. rhetoric against tax inversions has been "political theater" ahead of midterm elections and made clear that his company is still open to a potential tax-saving acquisition, according to Financial Times, which added Read's comment about not being “held hostage” over price would likely be read as a signal the company might look elsewhere after being rebuffed by AstraZeneca (AZN). The Fly notes that Bloomberg previously reported, citing people familiar with the matter, that Pfizer is looking at targets other than AstraZeneca, including Actavis (ACT). Shares of Actavis trading in New York are up 2% this morning. Reference Link
10:04 EDTSNYSanofi unit granted orphan status for treatment of Gaucher disease
Subscribe for More Information
07:42 EDTBBRYBlackBerry acquisition positive, says Wells Fargo
Subscribe for More Information
07:32 EDTBIIBBiogen, AbbVie announce ZINBRYTA DECIDE Phase 3 study results
Biogen (BIIB) and AbbVie (ABBV) announced the full results from the Phase 3 DECIDE clinical trial, which show ZINBRYTA, dosed subcutaneously once a month, demonstrated a statistically significant improvement in reducing disease activity in people with relapsing-remitting multiple sclerosis compared to AVONEX. These results are being presented at the Sixth Triennial Joint Meeting of the Americas Committee for Treatment and Research in Multiple Sclerosis and the European Committee for Treatment and Research in Multiple Sclerosis. Patients on ZINBRYTA demonstrated a statistically significant 45% reduction in annualized relapse rate compared to patients treated with AVONEX. Based on the efficacy and safety data from the ZINBRYTA clinical development program, Biogen Idec and AbbVie plan to file marketing applications for ZINBRYTA with regulatory authorities during 1H15.
September 11, 2014
18:35 EDTMCPOn The Fly: After Hours Movers
Subscribe for More Information
17:00 EDTMCPMolycorp announces closing of $400M financing arrangement
Molycorp, Inc. announced the successful close of its previously announced $400M financing arrangement with certain investment vehicles affiliated with Oaktree Capital Management, L.P. Under the arrangement, Oaktree will provide Molycorp and certain of the company's subsidiaries with up to $400M in secured financing through credit facilities and the sale and leaseback of certain equipment at the company's Mountain Pass facility. $250M of the financings has now been funded, with the remaining $150M available until April 30, 2016 if Molycorp achieves consolidated adjusted EBITDA of not less than $20.0M per quarter for two consecutive fiscal quarters, and production volume at its Mountain Pass facility of at least 4,000 metric tons per quarter for two consecutive fiscal quarters.
14:18 EDTBBRYBlackBerry looking into wearable products, CrackBerry says
Subscribe for More Information
09:00 EDTBBRYBlackBerry acquires Movirtu, terms not disclosed
Subscribe for More Information
08:11 EDTBBRYBlackBerry October volatility elevated into Q2 and outlook
Subscribe for More Information
07:31 EDTBIIBBiogen announces 5-year results from TECFIDERA ENDORSE Phase 3 study
Subscribe for More Information
07:31 EDTBIIBBiogen announces new data from Plegridy Phase 3 ADVANCE trial
Biogen Idec announced new data from the second year of its Phase 3 ADVANCE clinical trial that show the positive treatment effects of PLEGRIDY were maintained in people with relapsing forms of multiple sclerosis beyond the first year of the study. These results were presented at the sixth Triennial Joint Meeting of the Americas Committee for Treatment and Research in Multiple Sclerosis and the European Committee for Treatment and Research in Multiple Sclerosis in Boston. Post-hoc analyses from the two-year, Phase 3 ADVANCE clinical trial confirm that PLEGRIDY’s positive effects on reducing disease activity and disability progression were maintained in year two of the study. A significantly higher proportion of patients taking PLEGRIDY during both years of the study experienced no evidence of disease activity – defined as the absence of clinical and MRI disease activity over two years of treatment – compared to those who switched to PLEGRIDY from placebo. Also, those treated with PLEGRIDY for both years of the study had significant reductions in the risk of 24-week confirmed disability progression compared to patients treated with placebo during the first year. In addition, new data from the second year of ADVANCE show that patients who took PLEGRIDY throughout the study experienced statistically significant improvements in clinical and MRI outcomes – including annualized relapse rate, risk of relapse, risk of 24-week confirmed disability progression, and number of brain lesions – when compared to those who switched to PLEGRIDY after taking placebo for the first year. This new data also showed that the safety profile of PLEGRIDY was consistent between years one and two of the study.
05:27 EDTSNYGenzyme announces positive interim results from Lemtrada extension study
Subscribe for More Information
September 10, 2014
07:09 EDTSNYAmericas Committee for Treatment & Research in MS to hold a meeting
Subscribe for More Information
06:00 EDTBBRYStocks with implied volatility top IV index mean; BBRY YHOO
Subscribe for More Information
September 8, 2014
14:16 EDTSNYSanofi announces FDA approval of Menactra vaccine
Subscribe for More Information
09:27 EDTBIIBLeerink biotech analyst holds a luncheon meeting with a conference call
Biotech Analyst Schwartz provides an update on key trends and controversies for marketed MS therapies and discusses new data presented at ACTRIMS-ECTRIMS at a Luncheon Meeting with an Analyst/Industry conference call to be held in Boston on September 11 at 12:15 pm.
08:03 EDTACNGeneral Electric, Accenture launch Intelligent Pipeline Solution
Subscribe for More Information
07:15 EDTBIIB, PFEIBC Life Sciences to hold a conference
10th Annual Cell Line Development & Engineering Conference to be held in Berkeley, California on September 8-10.
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use